Skip to content

Study · Not a test of the peptide alone · 2024

1 result

Cerebrolysin Concentrate: Therapeutic Potential for Severe Oral Apraxia After Stroke: A Case Report.

Jeon H, Kim DY

Brain & NeuroRehabilitation17 Jun 2024

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Cerebrolysin.

  1. 01HumanNot a test of Cerebrolysin aloneCase report or seriesEfficacy outcome

    In a man with post-stroke oral apraxia, cerebrolysin concentrate with intensive rehabilitation preceded marked improvement in oral apraxia.

    In plain wordsIn a man with stroke, cerebrolysin concentrate with intensive rehabilitation preceded improved oral movements.

    Outcome
    IncreaseOral apraxia
    Study

    n = 1

    Outcome group
    Exercise and physical function · Nervous system and cognition

    Source sentences

    Summary
    After rehabilitation and administration of cerebrolysin concentrate, there was a marked recovery within a short period of time to the point where oral intake of a regular diet was possible, indicating a significant improvement in oral apraxia.
    2 context sentences
    Summary · context
    We present the case of a 72-year-old man with severe oral apraxia due to a left middle cerebral artery ischemic stroke involving the left insular cortex.
    Summary · context
    The patient received intravenous cerebrolysin concentrate in addition to intensive rehabilitation therapy from 23 days after onset.

    In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.